Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor-α.

Tsumura K, Suzuki A, Tsuzuki T, Tanimoto S, Kaneko H, Matsumura S, Imoto M, Umezawa K, Takahashi D, Toshima K.

Org Biomol Chem. 2011 Sep 21;9(18):6357-66. doi: 10.1039/c1ob05629h. Epub 2011 Jul 25.

PMID:
21789304
2.

Target-selective degradation of proteins by a light-activated 2-phenylquinoline-estradiol hybrid.

Suzuki A, Tsumura K, Tsuzuki T, Matsumura S, Toshima K.

Chem Commun (Camb). 2007 Nov 7;(41):4260-2.

PMID:
18217599
3.

Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.

Yu HN, Noh EM, Lee YR, Roh SG, Song EK, Han MK, Lee YC, Shim IK, Lee SJ, Jung SH, Kim JS, Youn HJ.

Biochem Biophys Res Commun. 2008 Dec 5;377(1):242-7. doi: 10.1016/j.bbrc.2008.09.111. Epub 2008 Oct 7.

PMID:
18835379
5.

P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.

Li HJ, Wang LY, Qu HN, Yu LH, Burnstock G, Ni X, Xu M, Ma B.

Mol Cell Endocrinol. 2011 May 16;338(1-2):28-37. doi: 10.1016/j.mce.2011.02.014. Epub 2011 Feb 26.

PMID:
21356271
6.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

7.

Chemical methods for degradation of target proteins using designed light-activatable organic molecules.

Tanimoto S, Takahashi D, Toshima K.

Chem Commun (Camb). 2012 Aug 11;48(62):7659-71. doi: 10.1039/c2cc30831b. Epub 2012 Jun 27.

PMID:
22739361
8.

Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.

Laïos I, Journe F, Laurent G, Nonclercq D, Toillon RA, Seo HS, Leclercq G.

J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):207-21.

PMID:
14672741
9.
10.
11.

Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.

Saha P, Fortin S, Leblanc V, Parent S, Asselin É, Bérubé G.

Steroids. 2012 Sep;77(11):1113-22. doi: 10.1016/j.steroids.2012.06.004. Epub 2012 Jul 16.

PMID:
22801351
12.

The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.

Freddie CT, Larsen SS, Bartholomaeussen M, Lykkesfeldt AE.

Mol Cell Endocrinol. 2004 Apr 30;219(1-2):27-36.

PMID:
15149724
13.

Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.

Ko YM, Wu TY, Wu YC, Chang FR, Guh JY, Chuang LY.

J Ethnopharmacol. 2011 Oct 11;137(3):1283-90. doi: 10.1016/j.jep.2011.07.056. Epub 2011 Aug 4.

PMID:
21840388
15.

Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells.

Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K.

Mol Cancer Ther. 2006 Mar;5(3):611-20.

17.

Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.

MacGregor Schafer J, Liu H, Levenson AS, Horiguchi J, Chen Z, Jordan VC.

J Steroid Biochem Mol Biol. 2001 Jul;78(1):41-50.

PMID:
11530283
19.

[Effects of exogenous ER beta expression on the cell growth properties of MCF-7 breast cancer cell line].

Zhu JH, Ye QN, Song ST, Jiang ZF, Yan JH, Hao CF, Huang CF.

Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):103-6. Chinese.

PMID:
16750012
20.

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.

Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):51-84. Review.

PMID:
10418981

Supplemental Content

Support Center